WESTON, FL - (NewMediaWire) - January 22, 2016 - Monaker Group (OTCQB: MKGI), (the "Company") or ("Monaker"), a technology driven travel and digital marketing company, announced today that Mr. Omar Jimenez has joined the Company as Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), effective on January 21, 2016. Mr. Jimenez has over 33 years of CFO and Senior Executive experience in Public and Private Corporations ranging from start-ups to over $400 million in Revenues across Travel & Hospitality, Real Estate and Insurance Industries.

Mr. Jimenez has held a variety of senior financial management positions including CFO at EpiCenter Development, a real estate developer with combined projects amounting to $6 billion, and President & CFO at American Leisure Holdings, Inc., with listings on the NASDAQ and London Stock Exchange focusing on leisure and business travel, hospitality & hotels, call centers and real estate development. Mr. Jimenez also served as Director of Operations for US Installation Group, Inc., a selling and installation group for The Home Depot, and CFO and VP of Onyx Group, Inc., a conglomerate with 700 employees and annual revenues exceeding $400 million. 

"Omar is an accomplished leader with extensive financial, operational and business development experience," said William Kerby, Chief Executive Officer and Chairman of the Board of Monaker Group. "Omar's outstanding track record in the Travel & Hospitality industry and his experience with US Installation Group, EpiCenter Development, and American Leisure make him an ideal senior executive to fulfill our Company's current and future needs. We are excited to have Omar join us as we launch the much anticipated Next Trip platform and become a significant player in the Alternative Lodging space."

"Monaker Group's positioning and build of the Next Trip platform is impressive, and I look forward to working with the team for expected growth over the next several years," stated Mr. Omar Jimenez. "I am excited to have the opportunity to work with Bill and the management team that they have assembled at Monaker. I believe this Company is at the forefront of innovation with what we believe is the most comprehensive and advanced travel booking engine. I look forward to developing strategies with them to build sustained value for stakeholders."

Monaker Group also announced today the resignation of Adam Friedman, the Company's Chief Financial Officer. Mr. Kerby added, "On behalf of the Company's Board of Directors, management team and employees, I want to thank Adam for his contributions, and effort building the infrastructure of Monaker Group." Mr. Friedman will assist the Company, as needed, to assure a smooth transition.

Mr. Jimenez is a Certified Public Accountant (CPA), Chartered Global Management Accountant (CGMA), and a Member of the AICPA and FICPA. Mr. Jimenez holds a B.B.A in Accounting and a B.B.A in Finance from the University of Miami and an M.B.A from Florida International University.

About Monaker Group: 
Monaker Group is a technology driven travel and digital marketing company. Core to the Company's services are key elements including technology, an extensive film library, media distribution, trusted brands and established partnerships that enhance product offerings and reach. Consumers are quickly adopting video for researching and educating themselves prior to purchases, and Monaker has carefully amassed video content, media distribution, key industry relationships and a prestigious Travel Brand as cornerstones for the development and successful deployment of core-technology on both proprietary and partnership platforms. Monaker recently launched its Video Tour Guides ("VTG") and customized video rich travel itinerary offerings, and will launch a new travel platform in early 2016. The new Travel Platform will include enhanced video, language conversion, and dynamic booking capabilities, all working together to assist the consumer in their decision and purchasing process. The platform is a combination of proprietary and licensed technology, connecting and searching both large travel suppliers and, perishing and alternative lodging inventories for the benefit of consumers and stakeholders. 

Safe Harbor Statement:
This press release contains forward-looking statements that involve risks and uncertainties concerning the plans and expectations of Monaker Group, Inc. These statements are only predictions and actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties, some of which are out of our control. The potential risks and uncertainties include, among others, or the expectations of future growth may not be realized. These forward-looking statements are made only as of the date hereof, and Monaker Group, Inc. undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. All forward looking statements are expressly qualified in their entirety by the "Risk Factors" and other cautionary statements included in Monaker Group, Inc.'s annual, quarterly and special reports, proxy statements and other public filings with the Securities and Exchange Commission ("SEC"), including, but not limited to, the Company's Annual Report on Form 10-K for the period ended February 28, 2015 which has been filed with the SEC and is available at the SEC's website at www.sec.gov.

FORT LAUDERDALE, FL - (NewMediaWire) - January 22, 2016 - Multimedia Platforms Inc. (OTCQB: MMPW) ("MMPW" or the "Company"), the only publicly traded LGBT media company, today announced that it is re-locating their headquarters to Los Angeles, California in conjunction with the launch of the WiRLD Digital Hub in February 2016; registration is now open at www.WiRLD.com.

"We are very excited to join the WiRLD development and marketing team, which will have us all headquartered in Los Angeles to oversee and support the rollout of WiRLD. Additionally, we have begun expanding our streaming video production, sales and customer service support," commented, Bobby Blair, Chief Executive Officer of Multimedia Platforms. "WiRLD has been a primary focus of Multimedia Platforms' mission to connect the LGBT global community and provide unprecedented opportunities for both members and advertisers alike. With our beta launch rapidly approaching next month, it is critical that our executive team, developers and WiRLD staff are together to ensure the timely and efficient launch."

"WiRLD is providing the LGBT community entertainment and content on one destination for the first time ever on this scale. In the second quarter 2016, we will be rolling out a powerful lineup of media programs, including web series and live on demand events, along with our Streaming Video Network platform that is designed to connect with our global LGBT community and build a loyal following," commented Michael Turner, President of Media Ventures & Digital Media.

Additionally, CEO, Bobby Blair, will be inducted into the GLBT Hall of Fame Class of 2015 on February 20, 2016.

About Multimedia Platforms:

Multimedia Platforms Inc. ("MMPW") is an industry-leading multimedia, technology and publishing company that delivers content and advertising to one of the most sought-after demographics in the world, the Lesbian, Gay, Bisexual and Transgender (LGBT) population. MMPW's top brands include Frontiers magazine, Florida Agenda, FunMaps, Guy magazine and Next magazine representing approximately 7.5 million readers and 4+ million unique online visitors, annually.

MMPW's WiRLD digital hub features a global newsstand, global business directory, community LGBT network, a first of the kind rewards program and an online entertainment network to launch during the second quarter of 2016. WiRLD is scheduled for beta launch in February 2016. 

For more information please visit www.multimediaplatformsinc.com, www.WiRLD.com, or follow us on Twitter at https://twitter.com/mmpworldwideinc. 

Safe Harbor Statement:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends, " "estimates," and other words of similar meaning. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing or required licenses, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

BOSTON, MA - (NewMediaWire) - January 22, 2016 -  InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today plans to align its operations and leadership with focus on its largest commercial markets in line with the continued execution of its carotid and neurovascular strategy which was launched in mid 2015. 

Key elements of the changes announced today include the recruitment of a new CEO, who will focus on the Company's immediate commercial and development activities in Europe in order to enhance operational efficiency and further improve the Company's cost structure. To ensure a smooth leadership transition, the Company's current CEO, Alan Milinazzo, has agreed to remain through the earlier of the appointment of the new CEO or June 30, 2016.

InspireMD also announced today that Isaac Blech joins the Company as Vice Chairman of the Board. Mr. Blech brings with him over 30 years of experience as a healthcare industry pioneer and investor, developing companies from early to profitable commercial stages, including multiple successful strategic acquisitions. Mr. Blech has an established record for shareholder value creation and has played a key role in some high profile company transformations within the life sciences sector.

Sol Barer, Chairman of the Board of InspireMD, commented, "We are very pleased to welcome Isaac Blech as Vice Chairman of InspireMD. Isaac's experience as an industry pioneer, taking new technologies from development to commercialization, will be instrumental as we continue with our efforts to introduce and develop markets that leverage our proprietary MicroNet™ technology. We also welcome Isaac's deep relationships and extensive professional network across multiple fields -- including the financial, pharmaceutical, biotechnology and medical device communities -- supporting our active efforts to validate our technology and capabilities." Dr. Barer continued, "Finally, we thank Alan Milinazzo for effectively taking the Company through its challenging transition. We are now well underway as we execute on our carotid and neurovascular strategy and look forward to announcing a new CEO who will focus the Company's present efforts towards Europe, the heart of our current commercial activities."

In connection with Mr. Blech's appointment, the Company agreed to award him options to acquire 780,000 shares of the Company's common stock on April 30, 2016, with vesting based on both time and the Company's achievement of milestones. Details of his board engagement are available in a Form 8-K filing along with an amendment to Mr. Milinazzo's employment agreement which should ensure a smooth executive leadership transition over the coming months.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard™ with MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

MGuard™ is CE Marked and not approved for sale in the U.S. by the U.S. Food and Drug Administration at this time.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

About CGuard™ EPS

The proprietary CGuard™ Embolic Prevention System (EPS) uses the same MicroNet™ technology featured on the MGuard™ and MGuard Prime™ coronary Embolic Protection Systems. The CGuard™ EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining excellent perfusion to the external carotid artery and branch vessels.

MicroNet™ is a bio-stable mesh woven from a single strand of 20 micron Polyethylene Terephthalate.

CGuard™ EPS is CE Marked and not approved for sale in the U.S. by the U.S. Food and Drug Administration at this time.

Forward-looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

BAY HARBOR ISLAND, FL - (NewMediaWire) - January 22, 2016 - Biotech Products Services & Research, Inc. (OTCQB: BPSR) ("Biotech" or the "Company") is proud to announce the launch of its wholly-owned subsidiary, General Surgical Florida, Inc. ("General Surgical"). 

The team at General Surgical will work towards establishing sales distribution channels of regenerative products to hospitals, physicians and third party distributors. Specifically, General Surgical will be providing access to advanced regenerative medical technologies (e.g., adipocyte, bone marrow and placental regenerative tissues), and expanding education services to providers in the Company's referral network.

Albert Mitrani, Biotech's CEO, commented, "This new branch of Biotech, we believe, will increase the depth of the patient referral network in our associated Beyond Cells subsidiary, as well as set the stage for sales and distribution of future product lines. We look forward to providing further information about General Surgical as developments occur."

About Biotech Products Services & Research, Inc.

Biotech Products Services & Research Inc., a Nevada corporation, focuses on a lifestyle of health and wellness. Our vision is to be a vertically integrated company, which primarily provides a patient referral service for integrative cellular therapies. Biotech also markets cellular products to doctors and hospitals.

Biotech aims to be the leader in the industry of innovative cell-based therapeutic with our unique strategy which will guide a future of customized disease management. Biotech also sells women's fashion products through its Ethan New York subsidiary as part of our vertically integrated health and wellness vision.
For more information investors can visit www.bpsrhealth.com. 

CAUTIONARY COMMENT REGARDING FORWARD-LOOKING STATEMENTS

The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for these forward-looking statements to be covered by the safe harbor provisions of the federal securities laws relating to forward-looking statements. This release contains forward-looking statements that reflect Biotech Products Services & Research, Inc., plans and expectations. In this press release and related comments by Company management, words like "expect," "anticipate," "estimate," "goal" and similar expressions are used to identify forward-looking statements, representing management's current judgment and expectations about possible future events.

Management believes these forward-looking statements and the judgments upon which they are based to be reasonable, but they are not guarantees of future performance and involve numerous known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, achievements or financial position to be materially different from any expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially from the forward-looking statements are set forth in our Form 10-K and other filings with the SEC. Other information can be obtained at www.bpsrhealth.com

Disclaimer: This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.